Outset Medical shares jumped 22.2% in the most recent trading session, driven by a surge in volume that was well above its 30-day daily average. This rally follows a series of analyst revisions to earnings estimates over the past month, although consensus projections for the next two quarters have shown only modest upward movement. Market participants will be closely watching whether this momentum can be sustained, given the potentially limited incremental upside implied by current analyst forecasts.

In its unaudited report for the quarter ended December 31, 2025, Outset generated $28.9 million in revenue, bringing full-year 2025 revenue to $119.5 million, a 5% increase over 2024’s $113.7 million. The company ended the year with $173 million in cash, restricted cash, cash equivalents and short-term investments, while net cash used in operations fell to under $50 million versus $116 million in 2024. This improvement in cash burn underscores management’s focus on operational efficiency and positions the company for continued investment in growth initiatives.

By the end of 2025, more than 1,000 healthcare sites had adopted Outset’s Tablo system, delivering approximately 1 million treatments annually and over 3 million cumulative treatments. The company also strengthened its governance with the appointment of Karen N. Prange to the board and Compensation Committee, replacing a long-serving director. Prange brings extensive commercial experience from roles at Boston Scientific, Henry Schein and Johnson & Johnson, which management expects will accelerate market penetration and channel development for Tablo in both hospital and outpatient settings.